Objectives: Renal outcomes after critical illness are seldom assessed despite strong correlation between chronic kidney disease and survival. Outside hospital, renal dysfunction is more strongly associated with mortality when assessed by serum cystatin C than by creatinine. The relationship between creatinine and longer term mortality might be particularly weak in survivors of critical illness. Design: Retrospective observational cohort study. Patients: In 3,077 adult ICU survivors, we compared ICU discharge cystatin C and creatinine and their association with 1-year mortality. Exclusions were death within 72 hours of ICU discharge, ICU stay less than 24 hours, and end-stage renal disease. Interventions: None.
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Superiority of Serum Cystatin C Over Creatinine in Prediction of Long-Term Prognosis at Discharge From ICU
Assessment of renal function in survivors of critical illness requires tests of renal function that accurately reflect risk of long-term adverse outcomes. The endogenous biomarkers of renal function, creatinine and cystatin C, both indirectly assess glomerular filtration rate (GFR) (8) . Although creatinine is standard, cystatin C has limited uptake worldwide despite potential superiority in prognostication of patients with CKD (9) . Furthermore, interpretation of serum creatinine in intensive care survivors may be confounded by decreased creatinine generation (10, 11) , thought to be a consequence of sustained muscle wasting observed in critical illness. This effect is doubly confounding as muscle wasting is itself associated with adverse patient outcomes (12) .
Cystatin C is produced in nucleated cells and less confounded by acute and chronic illness, changes in diet, and decreased muscle mass (13) . In patients with CKD, estimated GFR (eGFR) based on cystatin C better predicts mortality than eGFR based on creatinine, which demonstrates a J-shaped relationship with risk of death (9) . However, the relationship between cystatin C and longer term survival has not been compared with that of creatinine in the critically ill.
Accordingly, we examined 7 years of patient data from a major teaching hospital ICU where both serum creatinine and cystatin C are routinely measured. We hypothesized that, as a more accurate reflection of underlying renal function, cystatin C would be strongly associated with long-term risk of death after ICU discharge, whereas serum creatinine might perform comparatively poorly.
MATERIALS AND METHODS

Study Design
This cohort study was conducted in the multidisciplinary ICU at the Karolinska University Hospital, Solna, Sweden: a 13-bed unit with approximately 1,000 admissions yearly. The Stockholm Regional Ethics Committee approved the study, waiving informed consent due to retrospective observational nature of the study.
Inclusion and Exclusion Criteria
We screened all ICU patients admitted between October 2006 and December 2013. During this period, we only considered a patient's first ICU admissions of greater than 24 hours. We excluded deaths in ICU or within 3 days of ICU discharge, patients lacking linkage to mortality data, and any patients with ESRD prior to ICU admission or new ESRD with a chronic dialysis commencement date within 14 days of ICU discharge. Last, we excluded patients lacking cystatin C measurement near ICU discharge (up to 1 d prior or 2 d after ICU discharge date).
Laboratory Testing
Cystatin C was determined with a turbidimetric method (Gentian Cystatin C UDR-Kit for Beckman-Coulter Synchron and UniCel Systems, Ref A52761). Creatinine was determined with a modified Jaffe method (CREm, Creatinine, Ref 472525). We calculated eGFR for both markers using Chronic Kidney Disease Epidemiology Collaboration (14) .
Data Collection
Patients were monitored using the patient database management system Clinisoft (GE, Barrington, IL). From hospital electronic health records (EHRs) (Take Care; CompuGroup Medical, Koblenz, Germany), we linked diagnosis data from the index admission and prior clinical encounters with International Classification of Diseases, 10th Edition, coding for assessment of comorbidities and calculation of Charlson Comorbidity Index, Quan modification (15, 16) . Linkage to EHR laboratory information before and after ICU admission allowed assessment of premorbid hospital discharge and follow-up creatinine. AKI was defined by the Kidney Disease: Improving Global Outcomes criteria (17) as a 1.5-fold increase in serum creatinine from baseline during ICU admission or an absolute 0.3 mg/dL increase over a less than or equal to 48-hour period. Baseline creatinine was defined as the last value from 365 to 7 days prior to hospital admission or if unavailable, the value closest to the admission value. Follow-up creatinine was the most recent value available from 30 days to 1 year after hospital discharge. Swedish resident registration number (18) allowed identification of date of all deaths. Linkage with the Swedish Renal Registry allowed identification of patients with ESRD/time of first chronic dialysis.
Statistical Analyses
Statistical analysis was performed using R Development Core Team R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org using the packages "Survival" (19) , "SmoothHR" (20) , "icd" (21) , and "rms" (22) . Continuous variables are presented as median with interquartile range (IQR). Univariable comparisons were performed using the Wilcoxon rank-sum test, the Wilcoxon signed-rank test, and Fisher exact test for continuous, paired continuous, and binary data. Unadjusted survival data were stratified by quartiles of creatinine or cystatin C and plotted as a Kaplan-Meier estimator and compared using the log-rank test. A two-tailed p value of less than 0.05 was considered statistically significant.
Multivariable Modeling
To assess the independent effect of renal filtration markers on survival in the year after hospital discharge, multivariable Cox proportional hazard survival models were developed. To avoid concern regarding accuracy of eGFR equations in the ICU population, we modeled the relationship between absolute creatinine or cystatin C and mortality. We included age, sex, and comorbidity as covariates in our multivariable survival model as baseline factors likely to be associated with post-ICU survival and/or with renal function. In previous analyses of ICU survivors, comorbidity index was a stronger predictor of long-term mortality than ICU admission severity scoring (calibrated to short-term risk of death) (23) . To best illustrate the influence of AKI on the association of the filtration markers on survival, we repeated analyses considering only AKI or non-AKI patients. In all models, we tested the proportional hazards assumption by correlating the corresponding set of scaled Schoenfeld residuals with a KaplanMeier estimate of the survival function, and nonproportional covariates were handled by stratification for that variable. Based on general population data, we hypothesized that creatinine or cystatin C would be nonlinearly related to risk of death; accordingly, these variables were fitted to a penalized spline. The degree of curve smoothing in the final model was determined by an algorithm based on minimization of Akaike's Information Criterion. Finally, we included creatinine and cystatin C in a single age-, sex-, and comorbidity-adjusted multivariable model to explore the additive effects of these markers in combination.
RESULTS
Demographics
After exclusions, 3,077 survivors were included for primary analysis (Fig. S1 , Supplemental Digital Content 1, http://links.lww.com/ CCM/C667). By 90 days after ICU discharge, 318 (10.3%) died rising to 536 (17.4%) at 1 year. Nine patients developed new ESRD in the year after ICU discharge. Nonsurvivors were older, had greater comorbidity and higher Simplified Acute Physiology Score-3, more often developed AKI, and required renal replacement therapy. Patients dying in the year after ICU discharge had higher admission, peak and ICU discharge creatinine than long-term survivors, but these differences were more marked for cystatin C at all timepoints ( Table 1) . Importantly, while creatinine fell, from ICU admission to discharge, cystatin C rose over the same period (Table 1) .
Renal Function Markers and Mortality After ICU Discharge
Cystatin C and creatinine at ICU discharge differed distinctly in their association with mortality over the next 90 and 365 days ( Table 2 ). The lowest cystatin C quartile defined a lowrisk population with a 5.6% 1-year mortality, compared with 13.6% in the lowest creatinine quartile. Overall, rates of death were well separated with increasing rates of death between quartiles of discharge cystatin C, whereas for creatinine, only the upper quartile was separated (Fig. 1) .
Multivariable Survival Analysis
To detect nonlinear relationship between filtration markers and mortality risk, creatinine and cystatin C were fitted to penalized splines in a multivariable survival model including sex, stratified for age, and comorbidity index. Increasing cystatin C was near-linearly related to increasing hazard ratio (HR) for death; conversely, creatinine demonstrated a J-shaped relationship (Fig. 2) . These relationships persisted when patients with or without AKI were considered separately (Fig. S2 , Supplemental Digital Content 1, http://links.lww.com/CCM/C667). Considering both creatinine and cystatin C together in a new multivariable model including age, sex, and comorbidity, increasing cystatin C remained strongly associated with increasing HR for death; however, higher creatinine was then associated with "lower" hazard of death at all creatinine levels (Fig. 3) .
Relationship Between Cystatin C-and CreatinineBased eGFR
Median eGFR at ICU discharge based on creatinine was greater than using cystatin C (92 vs 68 mL/min/1.73 m 2 ; p < 0.001). Using cystatin C for eGFR identified 1,362 patients (44%) less than 60 mL/min/1.73 m 2 at ICU discharge compared with only 794 (26%) using creatinine-based eGFR. Despite a substantially larger population with low eGFR, there was similar mortality in the cystatin C group with eGFR less than 60 compared with that defined by creatinine eGFR (cystatin C: 386/1,362; 28% vs creatinine: 233/794; 29%) (Table S1, Supplemental Digital Content 1, http://links.lww.com/CCM/C667).
We examined cystatin C/creatinine divergence during ICU stay by comparing ratio of creatinine to cystatin C eGFR for different durations of ICU admission (Fig. S3 Digital Content 1, http://links.lww.com/CCM/C667). In admissions lasting 1-2 days, the median ratio was 1.01 (IQR, 0.87-1.24). However, with longer admissions, eGFR by creatinine was consistently greater than eGFR cystatin C. For ICU admissions of greater than 20 days, values of eGFR (creatinine) were a median of 2.1-fold (IQR, 1.7-2.8) greater than corresponding eGFR (cystatin C). Finally, to illustrate the timing of changes in creatinine and cystatin C after ICU admission, we examined changes in creatinine, cystatin C, and C-reactive protein (CRP) over the first 7 days of ICU admission and at ICU discharge in a subset of 516 patients with ICU admissions of greater than or equal to 7 days. In this analysis, creatinine progressively fell, whereas at the same time, cystatin C rose (Fig. S4 , Supplemental Digital Content 1, http://links. lww.com/CCM/C667). During this period, CRP had a biphasic profile and did not correlate with the two endogenous renal filtration markers.
To explore the discrepancy of cystatin C and creatinine at ICU discharge, we considered 743 patients without AKI in the ICU (where ICU discharge renal function would be expected to be similar to follow-up) who had a creatinine measurement in the 30-365 days after discharge and survived to 1 year. In this group, we compared cystatin C and creatinine eGFR at ICU discharge against follow-up creatinine eGFR (at a median of 267 d [IQR, 145-334] after hospital discharge). GFR based on cystatin C better agreed with CKD categorization at follow-up, particularly in the GFR range 30-60. In contrast, discharge creatinine eGFR overestimated follow-up GFR in all CKD categories (Fig. S5, 
DISCUSSION
Interpretation of Findings
In a large critically ill adult patient population, we found cystatin C was near-linearly associated with age-and comorbidity-adjusted 90-and 365-day mortality. In contrast, creatinine was unable to discriminate low-risk patients, showing a flattened J-shaped relationship with risk of death. Although in the majority of patients, discharge creatinine was not significantly predictive of risk of death, across the full range of measured values, cystatin C provided prognostic information.
In line with these findings, during ICU admission on average, creatinine fell, whereas in the same patient group, cystatin C rose resulting in a striking 24 mL/min/1.73 m 2 median difference in eGFR based on cystatin C versus creatinine at ICU discharge. Both markers supposedly reflect true underlying GFR, but clearly one, or both, fail to do so in this setting. If excretion of markers is similarly affected by renal function, the generation rate of one or both must be substantially altered during critical illness. Given that cystatin C is robustly related to risk of death, whereas creatinine is not, we believe that our findings are most compatible with cystatin C better reflecting underlying renal function. This conclusion is supported by the observation that in non-AKI patients, where underlying GFR would not be expected to change markedly during convalescence, ICU discharge cystatin C eGFR better correlated with follow-up CKD status than creatinine eGFR (Fig. S4 , Supplemental Digital Content 1, http://links.lww.com/CCM/ C667; Table S2 , Supplemental Digital Content 1, http://links. lww.com/CCM/C667).
Acute and chronic reduction in creatinine generation with muscle wasting may explain an inability to associate lower discharge creatinine with better prognosis, an interpretation strengthened by the finding that for short ICU admissions, cystatin C and creatinine eGFR at discharge are similar. With longer ICU stays, eGFR (creatinine) tends to be increasingly higher than eGFR (cystatin C), a finding compatible with progressive muscle wasting during prolonged critical illness (Fig.  S3 , Supplemental Digital Content 1, http://links.lww.com/ CCM/C667). Finally, when both markers were considered together in a survival model, increasing cystatin C remained strongly associated with mortality; however, increasing creatinine then became consistently associated with lower mortality, potentially reflecting lower mortality in patients with less muscle wasting (Fig. 3) .
Relation to Previous Studies
Assessment of renal function using creatinine has been shown to be confounded by progressive creatinine reduction associated with critical illness (10, 11) , and accounting for these reductions results in more than doubling of patients with potential CKD at ICU discharge. Decreased creatinine excretion, paralleling decreased production, has been demonstrated with prolonged critical illness (11) . In contrast, several studies suggest that cystatin C outperforms creatinine in ICU populations. In cardiovascular surgery, creatinine eGFR overestimated iohexol-measured GFR, whereas cystatin C eGFR well matched (24) . Similarly, in a general ICU patients, cystatin C eGFR was significantly lower than creatinine eGFR (25) . Reductions in creatinine generation have been demonstrated in an animal model of sepsis (26) ; notably, in this model, cystatin C production was not increased (27) , suggesting that any cystatin C elevation during critical illness is likely to reflect reduced renal clearance. The hypothesis that cystatin C production rises as an inflammatory response has also not been supported by previous comparisons with inflammatory markers in humans (28) , whereas, in our study, elevation in cystatin C was progressive and persistent despite resolution of systemic inflammation as indicated by fall in CRP (Fig. S4 , Supplemental Digital Content 1, http://links.lww.com/CCM/C667).
We have previously demonstrated an association between cystatin C but not creatinine and short-term ICU mortality in a small sample of patients (29) . This study extends those findings, demonstrating a consistent association between cystatin C at ICU discharge and longer term mortality in a much larger population of critically ill patients with and without AKI. Cystatin C has also been shown to better correlate with mortality in settings where creatinine values may be confounded by premorbid condition, including vascular surgery patients (30) , HIV patients (31), liver transplant recipients (32) , in acute heart failure (33) , and in the general population and patients with CKD (9).
Study Implications
Consequences of AKI include increased long-term risk of death, cardiovascular events, development of CKD, and ESRD (5, 6). Incomplete recovery from severe AKI is a well-recognized pathway to persistent and progressive CKD (34) , but recent studies suggest that apparently completely recovered AKI remains associated with a subsequent risk of CKD and death (5, 35) . Importantly, the majority of such patients do not receive kidney-directed follow-up. Our findings suggest that a substantial number of these patients could have significant renal dysfunction undetected by creatinine. Notably, in this study, the where ICU discharge renal function would be expected to be similar to follow-up 628 "extra" patients identified with an ICU discharge eGFR of less than 60 by cystatin C, but not creatinine, had similar risk of death to patients with eGFR less than 60 by creatinine-based calculation, suggesting that cystatin is correctly classifying patients at increased risk. Cystatin C has the potential to target a larger group of highrisk patients for specialist follow-up that might improve outcomes (36) and also to accurately identify a group of low-risk patients.
Strengths and Weaknesses
This study is the largest comparison between creatinine and cystatin C as markers of renal function in ICU patients. Highresolution data linkage allowed us to precisely identify the presence and severity of AKI in the ICU, to collect detailed comorbidity data, to remove chronic dialysis patients, and to obtain accurate all-cause mortality (37) .
A weakness of this study is lack of gold standard GFR. Despite circumstantial evidence that our results reflect limitations of serum creatinine as a GFR biomarker after critical illness, without reliable measurement of GFR, we cannot exclude the presence of increased cystatin C production that is independently associated with increased mortality (9, 38) . However, evidence suggests that such increases are not observed in clinical or experimental sepsis (23, 39) . Cystatin C measurements were confined to the ICU, that is, the timepoint of comparison, at ICU discharge, was one of only relative clinical stability, and renal recovery after AKI may still be occurring at this point. Our primary analysis concentrated on absolute values of creatinine and cystatin C. To compare predicted renal function from these markers, we used eGFR in secondary analyses, eGFR equations are unlikely to be accurate in the critically ill; however, the purpose of such comparison is only to better demonstrate the discrepancy between the markers and their agreement with baseline and follow-up. Finally, being a singlecenter study, our findings would need confirmation in groups of differing socioeconomic background and diverse ethnicity.
CONCLUSIONS
In a large population of critically ill patients, cystatin C progressively rose during ICU treatment, whereas creatinine fell despite both being markers of glomerular filtration. Levels of cystatin C after critical illness were strongly associated with 90-day and 1-year mortality both in AKI and non-AKI patients. Cystatin C identified almost twice as many patients as having clinically significant renal dysfunction at ICU discharge and was superior in CKD categorization in the year following the critical illness. Conversely, creatinine was poorly related to risk of death and, in isolation, had little value as a prognostic marker in the majority of patients. Cystatin C is likely to be the superior renal functional marker in survivors of major illness and should be investigated as a prognostic marker for patients at risk of CKD for follow-up and targeted intervention.
